As the COVID-19 omicron variant dashed hopes for a post-pandemic 2022, the US Food and Drug Administration on 29 December postponed domestic surveillance inspections through 19 January and foreign surveillance inspections through February.
The agency said 4 January it made the decision to ensure the safety of its employees and those of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?